Member Info for Chazzy2

Gwoods, you are the one who looks sad and lonely, not GB. I've never known anyone post as much utter tosh as you.

Bemma, plenty of contracts already in the pipeline. Massive rollout of latest Microtox equipment planned for later this year in response to confirmed orders. The £5m for Q1 is the ripple before the wave of orders. Not everything can be RNSd due to NDAs with various jurisdictions, but the deals have been done already. Modern Water are present in 50 countries and each one requires the latest updated equipment to be retrofitted.

GWOODS - I have an alternative suggestion, YOU sell up and move on and take Muggins with you as neither of you have any interest in the company and are blatantly deramping at every opportunity.

We'll see who's right over the coming months and years. I'm still baffled as to why you are so obsessed with DVRG.

So your measure of a company's success is it's share price is it? Revenue growth in triple digits over successive years clearly plays no part in your analysis of a company's performance. Have you failed to notice that many small cap sps have also been hammered. Perhaps we should blame covid and Ukraine on Gerry too.

Actually Muggins, I think you are the one who is losing it. Your constant relentless negativity is not only tiresome and unnecessary but is actually quite wearing now. Investors who have put their hard-earned money into DVRG want a balanced appraisal of a company, both the positives and the negatives. If you are to post negative aspects of a company -and I am the first to admit that CEOs don't always get it right - then do so in a constructive way which is meaningful and helpful to shareholders alike. There are plenty of companies out there which are performing less well than DVRG and yet you never mention any of them. Why is that I wonder? Your constant one-sided negativity however only reveals you to be someone with a personal grudge against both GB and DVRG. If you have a personal issue with the company, take it up with the company. You clearly have no faith in the company so why post at all on this board. Find a company you are interested in, if that is at all possible.

Exactly Davde, guidance of £24m still stands for 2022. Best to ignore Muggins. He's a serial deramper with a personal gripe against DVRG. He never posts about any other company!!

Too many investors conflate sp movement with performance - a sure fire way to lose money. Gerry can't control the sp but he's certainly delivering on rapid growth of the company. Ignore the sp and focus on the fundamentals. The sp always catches up!

Vascular, yes you are correct - the figures are $ not £, however still substantial numbers assuming the calculation still stands.

Smeeno, this is from the RNS of 11th March:

*Serviced Lease explanation: Of the £5m production orders, 27 Microtox CTM units with a sales value of $1.08m are to be installed on a 60 month serviced lease with monitoring and consumables at $40,000 per month. This is $480,000 over the first 12 months from installation date resulting in $2.4m over 5-years.

I may be mistaken , but if production volumes are to increase to 200 units per month, or 2400 units per year, the annual serviced lease revenue would increase to 2400/27 x £480,000 = £42.7 million per year. 200 units per month is to commence later this year. This is then annual recurring revenue. This would not include revenue from Labskin or Skin Trust Club which we know are also both growing at a phenomenal rate. So the potential is clearly massive here.

"*Serviced Lease explanation: Of the £5m production orders, 27 Microtox CTM units with a sales value of $1.08m are to be installed on a 60 month serviced lease with monitoring and consumables at $40,000 per month. This is $480,000 over the first 12 months from installation date resulting in $2.4m over 5-years."
Unless I'm mistaken, and I'd appreciate anyone's comments on this, this suggests that the annual revenue from just 27 microtox CTM units is $480,000. However mass rollout of 200 units per month will commence by H2. If we assume then that 2400 units are rolled out per year, that equates to recurring annual service revenue of $42 million per year!
And this is just the start of the roll out of water monitoring units...and does not include revenue from Labskin or Skin trust Club.

Ssti, so glad you enjoyed the presentation!

Great presentation. Very impressed with Mo and his very detailed and thorough presentation. He appears to have great vision for the future of the core business and many ideas for expanding the business. Cathal seems really determined now to crack on with the spin outs which is also really encouraging.

Yes very reassuring RNS. Across the year 24m is definitely achievable when you consider this doesn't include any Skin Trust Club revenue. We'll done Gerry and the team!

Thanks once again Wally for your excellent notes - much appreciated!

The market cap is now approaching this year's projected revenues. Incredibly cheap now.

Encouraging news which is certainly needed at the moment.

Good risk/reward ratio at these levels. With several shots on goal just one in the net could multibag the shareprice. In the run up to POLB001 human challenge trial results in the autumn there should be a steady increase in sp in anticipation of successful results. Probably then a good time to top slice, leaving you with a free ride.

Great news Gerry. Sounds like Skin Trust Club is going great guns. Looking forward to Skin Trust Medical also.

Nice find Mr T. How much more evidence do the doubters need?